These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33431416)

  • 21. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
    Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates.
    Buil JB; Brüggemann RJM; Bedin Denardi L; Melchers WJG; Verweij PE
    J Antimicrob Chemother; 2020 Sep; 75(9):2582-2586. PubMed ID: 32516368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020).
    Pfaller MA; Huband MD; Rhomberg PR; Bien PA; Castanheira M
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0102822. PubMed ID: 36286491
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Fakhim H; Chowdhary A; Prakash A; Vaezi A; Dannaoui E; Meis JF; Badali H
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.
    Valentín A; Cantón E; Pemán J; Fernandez-Rivero ME; Tormo-Mas MA; Martínez JP
    J Antimicrob Chemother; 2016 Dec; 71(12):3449-3452. PubMed ID: 27543657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
    Seifert H; Aurbach U; Stefanik D; Cornely O
    Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro synergy of echinocandins with triazoles against fluconazole-resistant Candida parapsilosis complex isolates.
    Ahmadi A; Mahmoudi S; Rezaie S; Hashemi SJ; Dannaoui E; Badali H; Ghaffari M; Aala F; Izadi A; Maleki A; Meis JF; Khodavaisy S
    J Glob Antimicrob Resist; 2020 Jun; 21():331-334. PubMed ID: 31715297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.
    Messer SA; Carvalhaes CG; Castanheira M; Pfaller MA
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115007. PubMed ID: 32081523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
    Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
    Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
    Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
    J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris
    John LLH; Thomson DD; Bicanic T; Hoenigl M; Brown AJP; Harrison TS; Bignell EM
    Antimicrob Agents Chemother; 2023 Jun; 67(6):e0164522. PubMed ID: 37162367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
    Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
    J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of the novel sixth
    Khan T; Faysal NI; Hossain MM; Mah-E-Muneer S; Haider A; Moon SB; Sen D; Ahmed D; Parnell LA; Jubair M; Chow NA; Chowdhury F; Rahman M
    Microbiol Spectr; 2024 Jul; 12(7):e0354023. PubMed ID: 38842332
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
    Seyedmousavi S; Meletiadis J; Melchers WJ; Rijs AJ; Mouton JW; Verweij PE
    Antimicrob Agents Chemother; 2013 Feb; 57(2):796-803. PubMed ID: 23183435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Vitek 2 system for antifungal susceptibility testing of
    Siopi M; Pachoulis I; Leventaki S; Spruijtenburg B; Meis JF; Pournaras S; Vrioni G; Tsakris A; Meletiadis J
    J Clin Microbiol; 2024 Apr; 62(4):e0152823. PubMed ID: 38501836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activities of nine antifungal agents against Candida auris biofilms.
    Chatzimoschou A; Giampani A; Meis JF; Roilides E
    Mycoses; 2021 Apr; 64(4):381-384. PubMed ID: 33270284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.